Home › Stock analysis › ABOS
Acumen Pharmaceuticals (ABOS) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
What changed since yesterday
- Closed at $1.69, +1.20% vs the prior close of $1.67.
- Volume 449.34K shares, 1.0x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
ABOS rises 1.2% to $1.69. Closed at $1.69, +1.20% vs the prior close of $1.67. Day range $1.62–$1.72, opened at $1.67.
Last close$1.69+1.20%
Day range1.62–1.72
Open1.67
Volume449.34K
52-week range1.50–3.60
Avg volume (20d)607.14K
ABOS daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — ABOS rises 1.2% to $1.69
- Closed at $1.69, +1.20% vs the prior close of $1.67. Day range $1.62–$1.72, opened at $1.67.
- Volume was 449.34K shares, 1.0x its 50-day average of 470.96K.
- Price is -33.9% vs its 50-day average ($2.56) and -32.4% vs its 200-day average ($2.50).
- 52-week range $1.50–$3.60; today's close sits at 9% of that range, 53.1% below the 52-week high.
Oct 15, 2026 — ABOS slides 4.3% to $1.67, a 6-month low, 4 down days in a row
- Closed at $1.67, -4.30% vs the prior close of $1.75. Day range $1.66–$1.75, opened at $1.71.
- Volume was 602.50K shares, 1.3x its 50-day average of 464.87K.
- Price is -35.0% vs its 50-day average ($2.57) and -33.2% vs its 200-day average ($2.50).
- 52-week range $1.50–$3.60; today's close sits at 8% of that range, 53.6% below the 52-week high.
- That makes 4 straight losses.
Oct 14, 2026 — ABOS slides 3.9% to $1.75, a 6-month low, 3 down days in a row
- Closed at $1.75, -3.86% vs the prior close of $1.82. Day range $1.71–$1.87, opened at $1.81.
- Volume was 619.80K shares, 1.4x its 50-day average of 458.14K.
- Price is -32.4% vs its 50-day average ($2.58) and -30.3% vs its 200-day average ($2.50).
- 52-week range $1.50–$3.60; today's close sits at 12% of that range, 51.5% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — ABOS slides 10.1% to $1.82, a 6-month low
- Closed at $1.82, -10.15% vs the prior close of $2.02. Day range $1.81–$2.00, opened at $2.00.
- Volume was 646.10K shares, 1.4x its 50-day average of 449.77K.
- Price is -29.9% vs its 50-day average ($2.59) and -27.5% vs its 200-day average ($2.50).
- 52-week range $1.50–$3.60; today's close sits at 15% of that range, 49.6% below the 52-week high.
Oct 12, 2026 — ABOS slides 5.6% to $2.02, a 6-month low
- Closed at $2.02, -5.61% vs the prior close of $2.14. Day range $2.00–$2.14, opened at $2.14.
- Volume was 291.50K shares, 0.6x its 50-day average of 449.20K.
- Price is -22.2% vs its 50-day average ($2.60) and -19.4% vs its 200-day average ($2.51).
- 52-week range $1.50–$3.60; today's close sits at 25% of that range, 43.9% below the 52-week high.
Oct 9, 2026 — ABOS rises 1.9% to $2.14
- Closed at $2.14, +1.90% vs the prior close of $2.10. Day range $2.08–$2.17, opened at $2.12.
- Volume was 357.50K shares, 0.8x its 50-day average of 448.72K.
- Price is -17.7% vs its 50-day average ($2.60) and -14.7% vs its 200-day average ($2.51).
- 52-week range $1.50–$3.60; today's close sits at 30% of that range, 40.6% below the 52-week high.
Oct 8, 2026 — ABOS ends flat (+0.0%) to $2.10
- Closed at $2.10, +0.00% vs the prior close of $2.10. Day range $2.02–$2.13, opened at $2.09.
- Volume was 505.20K shares, 1.1x its 50-day average of 448.27K.
- Price is -19.3% vs its 50-day average ($2.60) and -16.3% vs its 200-day average ($2.51).
- 52-week range $1.50–$3.60; today's close sits at 29% of that range, 41.7% below the 52-week high.
Oct 7, 2026 — ABOS jumps 3.4% to $2.10
- Closed at $2.10, +3.45% vs the prior close of $2.03. Day range $2.00–$2.17, opened at $2.02.
- Volume was 623.10K shares, 1.4x its 50-day average of 452.92K.
- Price is -19.3% vs its 50-day average ($2.60) and -16.3% vs its 200-day average ($2.51).
- 52-week range $1.50–$3.60; today's close sits at 29% of that range, 41.7% below the 52-week high.
Oct 6, 2026 — ABOS slides 4.7% to $2.03, a 6-month low
- Closed at $2.03, -4.69% vs the prior close of $2.13. Day range $2.00–$2.14, opened at $2.13.
- Volume was 562.90K shares, 1.3x its 50-day average of 446.55K.
- Price is -22.1% vs its 50-day average ($2.60) and -19.1% vs its 200-day average ($2.51).
- 52-week range $1.50–$3.60; today's close sits at 25% of that range, 43.6% below the 52-week high.
Oct 5, 2026 — ABOS jumps 4.4% to $2.13
- Closed at $2.13, +4.41% vs the prior close of $2.04. Day range $2.02–$2.16, opened at $2.04.
- Volume was 713.90K shares, 1.6x its 50-day average of 436.80K.
- Price is -18.3% vs its 50-day average ($2.61) and -15.1% vs its 200-day average ($2.51).
- 52-week range $1.50–$3.60; today's close sits at 30% of that range, 40.8% below the 52-week high.
Oct 2, 2026 — ABOS dips 1.4% to $2.04, a 6-month low, 4 down days in a row
- Closed at $2.04, -1.45% vs the prior close of $2.07. Day range $2.02–$2.10, opened at $2.10.
- Volume was 580.50K shares, 1.3x its 50-day average of 430.91K.
- Price is -21.8% vs its 50-day average ($2.61) and -18.7% vs its 200-day average ($2.51).
- 52-week range $1.50–$3.60; today's close sits at 26% of that range, 43.3% below the 52-week high.
- That makes 4 straight losses.
ABOS latest news & SEC filings
Every SEC filing by or about ABOS in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 16, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Aug 12, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Aug 12, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$32.72M (prior year -$40.95M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.45 (prior year -$0.68) (loss narrowed vs Jun 30, 2025)
Aug 12, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Things to know before you trade ABOS
- Last results release: Aug 12, 2026 (8-K Item 2.02). Previous ones: May 12, 2026, Mar 26, 2026, Nov 12, 2025. Based on that rhythm, the next report is likely around Nov 11, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.74% (largest 13.0%). That is a volatile stock.
- Liquidity: about 607.14K shares (≈$1.03M) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $1.69 vs a range of $1.50–$3.60 (9% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Derrell Porter sold 13,040 shares on Jun 17, 2026.
- Latest filings: 8-K Sep 16, 2026; 10-Q Aug 12, 2026; 8-K Aug 12, 2026.
- Share count: 72.32M shares outstanding (Aug 7, 2026), +19.4% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
ABOS market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 1.67 | 1.72 | 1.62 | 1.69 | 449.34K |
| Oct 15, 2026 | 1.71 | 1.75 | 1.66 | 1.67 | 602.50K |
| Oct 14, 2026 | 1.81 | 1.87 | 1.71 | 1.75 | 619.80K |
| Oct 13, 2026 | 2.00 | 2.00 | 1.81 | 1.82 | 646.10K |
| Oct 12, 2026 | 2.14 | 2.14 | 2.00 | 2.02 | 291.50K |
| Oct 9, 2026 | 2.12 | 2.17 | 2.08 | 2.14 | 357.50K |
| Oct 8, 2026 | 2.09 | 2.13 | 2.02 | 2.10 | 505.20K |
| Oct 7, 2026 | 2.02 | 2.17 | 2.00 | 2.10 | 623.10K |
| Oct 6, 2026 | 2.13 | 2.14 | 2.00 | 2.03 | 562.90K |
| Oct 5, 2026 | 2.04 | 2.16 | 2.02 | 2.13 | 713.90K |
| Oct 2, 2026 | 2.10 | 2.10 | 2.02 | 2.04 | 580.50K |
| Oct 1, 2026 | 2.22 | 2.29 | 2.07 | 2.07 | 832.80K |
| Sep 30, 2026 | 2.25 | 2.45 | 2.10 | 2.22 | 1.48M |
| Sep 29, 2026 | 2.30 | 2.42 | 2.22 | 2.24 | 1.09M |
| Sep 28, 2026 | 2.22 | 2.38 | 2.19 | 2.30 | 856.30K |
| Sep 25, 2026 | 2.25 | 2.30 | 2.22 | 2.24 | 235.30K |
| Sep 24, 2026 | 2.30 | 2.34 | 2.22 | 2.23 | 265.80K |
| Sep 23, 2026 | 2.63 | 2.63 | 2.30 | 2.31 | 467.90K |
| Sep 22, 2026 | 2.61 | 2.70 | 2.60 | 2.65 | 567.70K |
| Sep 21, 2026 | 2.63 | 2.64 | 2.56 | 2.59 | 395.20K |
About Acumen Pharmaceuticals
Acumen Pharmaceuticals (ABOS) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in NEWTON, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1576885.
ABOS board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Kimberlee C Drapkin | Director | Jun 5, 2026 |
| Nathan B Fountain | Director | Jun 10, 2026 |
| George Golumbeski | Director | Jun 5, 2026 |
| Jeffrey L. Ives | Director | Jun 5, 2026 |
| Peter Kolchinsky | Director | Jun 5, 2026 |
| Daniel Joseph Oconnell | Chief Executive Officer | Jan 23, 2026 |
| Derrell Porter | Director | Jun 17, 2026 |
| Capital Management, L.P. Ra | Director | Jun 5, 2026 |
| Capital Healthcare Fund Lp Ra | Director | Jun 5, 2026 |
| Capital Nexus Fund Ii, L.P. Ra | Director | Jun 5, 2026 |
| Rajeev M. Shah | Director | Jun 5, 2026 |
| John A Iii Stalfort | Director | Jun 5, 2026 |
| Laura Stoppel | Director | Jun 5, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Russell Barton | Chief Operating Officer | Jan 23, 2026 |
| James J. Doherty | President and CDO | Jan 21, 2026 |
| Derek M Meisner | Chief Legal Officer & Corp Sec | Mar 10, 2026 |
| Daniel Joseph Oconnell | Chief Executive Officer | Jan 23, 2026 |
| Amy Schacterle | Chief Regulatory Officer | Jan 21, 2026 |
| Eric Siemers | Chief Medical Officer | Jan 23, 2026 |
| Matt Zuga | CFO & Chief Business Officer | Jan 23, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 17, 2026 | Derrell Porter | Sale | 13,040 | $2.33 |
| Jun 17, 2026 | Derrell Porter | Sale | 13,040 | $2.33 |
| Jun 17, 2026 | Derrell Porter | Sale | 13,040 | $2.33 |
| Jun 17, 2026 | Derrell Porter | Sale | 13,040 | $2.33 |
| Jun 16, 2026 | Derrell Porter | Sale | 12,800 | $2.33 |
| Jun 16, 2026 | Derrell Porter | Sale | 12,800 | $2.33 |
| Jun 16, 2026 | Derrell Porter | Sale | 12,800 | $2.33 |
| Jun 16, 2026 | Derrell Porter | Sale | 12,800 | $2.33 |
| Jun 15, 2026 | Derrell Porter | Sale | 6,460 | $2.35 |
| Jun 15, 2026 | Derrell Porter | Sale | 6,460 | $2.35 |
| Jun 15, 2026 | Derrell Porter | Sale | 6,460 | $2.35 |
| Jun 15, 2026 | Derrell Porter | Sale | 6,460 | $2.35 |
| Jun 9, 2026 | Nathan B Fountain | Sale | 6,400 | $2.23 |
| Jun 9, 2026 | Nathan B Fountain | Sale | 6,400 | $2.23 |
| Jun 9, 2026 | Nathan B Fountain | Sale | 6,400 | $2.23 |
ABOS financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-121.33M | -2.00 | $-115.54M |
| Dec 31, 2024 | — | $-102.33M | -1.71 | $-86.22M |
| Dec 31, 2023 | — | $-52.37M | -1.08 | $-43.06M |
| Dec 31, 2022 | — | $-42.86M | -1.06 | $-35.15M |
| Dec 31, 2021 | — | $-100.61M | -5.02 | $-17.96M |
Latest balance sheet: total assets $116.01M, total liabilities $58.74M, cash $59.44M (as of Jun 30, 2026).
ABOS earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 12, 2026 | 8-K Item 2.02 (results) | $2.51 |
| May 12, 2026 | 8-K Item 2.02 (results) | $2.48 |
| Mar 26, 2026 | 8-K Item 2.02 (results) | $2.55 |
| Nov 12, 2025 | 8-K Item 2.02 (results) | $1.95 |
| Aug 12, 2025 | 8-K Item 2.02 (results) | $1.26 |
| May 13, 2025 | 8-K Item 2.02 (results) | $1.05 |
| Mar 27, 2025 | 8-K Item 2.02 (results) | $1.23 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $2.67 |
| Aug 13, 2024 | 8-K Item 2.02 (results) | — |
| May 14, 2024 | 8-K Item 2.02 (results) | — |
| Mar 26, 2024 | 8-K Item 2.02 (results) | — |
| Mar 19, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on ABOS
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.